TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22924433

Group type: EXPERIMENTAL
Intervention: Idarubicin-induced apoptosis >3 KU
Number of subjects: 109
Study: 22924536

Group type: EXPERIMENTAL
Intervention: ATP1A3 gene mutations (R756H and D923N) in children
Number of subjects: 2
Study: 22925036

Group type: EXPERIMENTAL
Intervention: Fondaparinux 1.5 mg qd for 6 to 15 days
Number of subjects: 206
Study: 22925178

Group type: EXPERIMENTAL
Intervention: Heparin-grafted membrane with ordinary heparin dose
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 45
Study: 22925750

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 148
Study: 22927100

Group type: EXPERIMENTAL
Intervention: Scoring balloon for side branch and drug-eluting stent for main vessel
Number of subjects: 93
Study: 22927248

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell (MSC) treatment
Number of subjects: 0
Study: 22927452

Group type: EXPERIMENTAL
Intervention: GII.4 norovirus challenge (5 x 10^4 RT-PCR units)
Number of subjects: 40
Study: 22927751

Group type: EXPERIMENTAL
Intervention: InterVapor treatment
Number of subjects: 44
Study: 22928607

Group type: EXPERIMENTAL
Intervention: Affected subjects with ruptured intracranial aneurysm
Number of subjects: 2794

Group type: EXPERIMENTAL
Intervention: Affected subjects
Number of subjects: 2794

Group type: EXPERIMENTAL
Intervention: Affected subjects ≤60 years of age
Number of subjects: 2794

Group type: EXPERIMENTAL
Intervention: Affected subjects ≥60 years of age
Number of subjects: 2794
Study: 22928669

Group type: EXPERIMENTAL
Intervention: Basic score based on clinical history data (e.g. hypertension, myocardial infarction, atrial fibrillation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advanced score including additional factors such as blood-based biomarkers and results of vascular imaging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Advanced score clinical utility assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined vascular end-point
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual components of the composite end-point
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patterns and time points of risk transitions
Number of subjects: 0
Study: 22929184

Group type: EXPERIMENTAL
Intervention: Idursulfase weekly group
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Idursulfase treatment group (extension phase)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo group (extension phase)
Number of subjects: 312
Study: 22929546

Group type: EXPERIMENTAL
Intervention: Facial burns
Number of subjects: 0

Group type: COMPARATOR
Intervention: No facial burns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teenagers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parents with higher education
Number of subjects: 0
Study: 22929544

Group type: EXPERIMENTAL
Intervention: Multi-Center Benchmarking Study of four burn centers
Number of subjects: 1140
Study: 22929547

Group type: EXPERIMENTAL
Intervention: Hand burns
Number of subjects: 438
Study: 22929545

Group type: EXPERIMENTAL
Intervention: Burn Outcomes Questionnaire (BOQ)
Number of subjects: 1140

Group type: EXPERIMENTAL
Intervention: Short-Form Psychosocial Questionnaire
Number of subjects: 1140
Study: 22929549

Group type: EXPERIMENTAL
Intervention: Adolescent self-assessment using the BOQ
Number of subjects: 355
Study: 22929551

Group type: EXPERIMENTAL
Intervention: Hospitalization costs
Number of subjects: 230
Study: 22929550

Group type: EXPERIMENTAL
Intervention: Short-Form Psychosocial Questionnaire (SFPQ)
Number of subjects: 830

Group type: EXPERIMENTAL
Intervention: Long-Form Psychosocial Questionnaire (LFPQ)
Number of subjects: 830
Study: 22930806

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (oral) for 14 days
Number of subjects: 48
Study: 22931751

Group type: EXPERIMENTAL
Intervention: Initial Period
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eligible patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Final Period
Number of subjects: 0
Study: 22932225

Group type: EXPERIMENTAL
Intervention: Melanoma-specific T(CM) clones after in vitro expansion and differentiation
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Melanoma-specific T(CM) with high relative IL-2 production
Number of subjects: 5
Study: 22932256

Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT)
Number of subjects: 1163

Group type: COMPARATOR
Intervention: Low-density lipoprotein cholesterol (LDLC)
Number of subjects: 1163

Group type: EXPERIMENTAL
Intervention: 27-hydroxycholesterol (27OHC)
Number of subjects: 1163
Study: 22932804

Group type: EXPERIMENTAL
Intervention: Recombinant monomeric sCD40L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PBMCs cultured with sCD40L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: sCD40L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preexisting sCD40L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MDSCs from cancer patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: T-cells cocultured with MDSCs
Number of subjects: 0
Study: 22933539

Group type: EXPERIMENTAL
Intervention: FFA suppression
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: IVGTT nadir palmitate concentration, VAT, UBSQ fat, fitness, and age
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: meal nadir palmitate concentration, UBSQ fat, fitness, and sex
Number of subjects: 200
Study: 22933606

Group type: EXPERIMENTAL
Intervention: Chronic periodontal inflammation model; periostin levels measured at baseline, 2 weeks, and 4 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic periodontal inflammation model; alveolar bone loss measured at baseline, 2 weeks, and 4 weeks.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between periostin levels and alveolar bone loss.
Number of subjects: 0
Study: 22933843

Group type: EXPERIMENTAL
Intervention: Integrated Treatment
Number of subjects: 0
Study: 22935168

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (OLAI)
Number of subjects: 1182
Study: 22935398

Group type: EXPERIMENTAL
Intervention: Fazekas score 2
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Fazekas score 3
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Wahlund scores >10
Number of subjects: 101
Study: 22935486

Group type: EXPERIMENTAL
Intervention: Peginesatide administered intravenously every 4 weeks for up to 6 doses.
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Cohorts using tiered dose conversion tables.
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Cohorts using an erythropoiesis-stimulating agent-free interval.
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Safety profile of peginesatide.
Number of subjects: 164
Study: 22935621

Group type: EXPERIMENTAL
Intervention: 400-μg sublingual misoprostol
Number of subjects: 100
Study: 22935620

Group type: EXPERIMENTAL
Intervention: 400-μg sublingual misoprostol as first-line treatment
Number of subjects: 90
Study: 22936711

Group type: EXPERIMENTAL
Intervention: Riociguat (1.0-2.5 mg three times daily for 12 weeks)
Number of subjects: 22
Study: 22936827

Group type: EXPERIMENTAL
Intervention: Bone marrow plasma from CHF patients
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: BM plasma stimulation of human mesenchymal cells from CHF patients
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Multivariate regression analysis
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 153
Study: 22938148

Group type: EXPERIMENTAL
Intervention: Portable electrocardiogram (ECG) recording during the marathon
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: 3 Tesla brain magnetic resonance imaging (MRI)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Clinical examination (CE), carotid ultrasound imaging (CUI), serial blood sampling (BS)
Number of subjects: 110
Study: 22938715

Group type: EXPERIMENTAL
Intervention: Pulmonary artery enlargement (PA:A ratio > 1)
Number of subjects: 0
Study: 22939385

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 22939402

Group type: EXPERIMENTAL
Intervention: Nexplanon (etonogestrel implant)
Number of subjects: 301
Study: 22939560

Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BS)
Number of subjects: 23
Study: 22939663

Group type: EXPERIMENTAL
Intervention: Two doses of seven-valent pneumococcal conjugate vaccine (PCV) given at a 4-week interval
Number of subjects: 429

Group type: COMPARATOR
Intervention: One dose of seven-valent pneumococcal conjugate vaccine (PCV)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Seven-valent PCV vaccination
Number of subjects: 429

Group type: COMPARATOR
Intervention: HAART
Number of subjects: 429
Study: 22939945

Group type: EXPERIMENTAL
Intervention: Extended-release quetiapine
Number of subjects: 25
Study: 22940027

Group type: EXPERIMENTAL
Intervention: 4 mg/kg artesunate at 0, 24, and 48 h, 15 mg/kg mefloquine at 72 h, and 10 mg/kg mefloquine at 96 h
Number of subjects: 168
Study: 22940371

Group type: COMPARATOR
Intervention: Grapefruit juice (240 mL twice daily for 4 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Seville orange juice (240 mL twice daily for 4 days)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Colchicine with grapefruit juice
Number of subjects: 44

Group type: COMPARATOR
Intervention: Colchicine with Seville orange juice
Number of subjects: 44
Study: 22940493

Group type: EXPERIMENTAL
Intervention: HPV infection (any type)
Number of subjects: 16782

Group type: EXPERIMENTAL
Intervention: Cytological abnormalities
Number of subjects: 16782

Group type: EXPERIMENTAL
Intervention: Behavioral risk factors (multivariable analysis)
Number of subjects: 16782

Group type: EXPERIMENTAL
Intervention: History of STI (excluding Chlamydia trachomatis)
Number of subjects: 16782

Group type: EXPERIMENTAL
Intervention: 3+ sexual partners in the past 12 months
Number of subjects: 16782
Study: 22941123

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Current medical therapy
Number of subjects: 4
Study: 22941849

Group type: EXPERIMENTAL
Intervention: Morphine bolus for intraoperative analgesia
Number of subjects: 146
Study: 22942205

Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (<50 nmol/L)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Vitamin D status
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Vitamin D status and PSI score
Number of subjects: 272
Study: 22943030

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for adherence and depression (CBT-AD), 10 to 12 sessions
Number of subjects: 9
Study: 22943074

Group type: EXPERIMENTAL
Intervention: Palivizumab 15 mg/kg, administered as 3 to 5 monthly injections over the RSV season.
Number of subjects: 100
Study: 22943924

Group type: EXPERIMENTAL
Intervention: Anagrelide hydrochloride (1 mg BID) in young patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Anagrelide hydrochloride (1 mg BID) in elderly patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3-hydroxy-anagrelide in young patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3-hydroxy-anagrelide in elderly patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Anagrelide t1/2 in young patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Anagrelide t1/2 in elderly patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3-hydroxy-anagrelide t1/2 in young patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3-hydroxy-anagrelide t1/2 in elderly patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adverse events monitoring
Number of subjects: 24
Study: 22944906

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at doses of 0.05, 0.10, and 0.20 μg/kg per minute
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion combined with exercise testing
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Targeted genetic testing of abnormal patients
Number of subjects: 170
Study: 22945767

Group type: EXPERIMENTAL
Intervention: Biodegradable polymer-based sirolimus-eluting stents
Number of subjects: 440

Group type: COMPARATOR
Intervention: Prolonged clopidogrel therapy (>6 months)
Number of subjects: 440
Study: 22946484

Group type: EXPERIMENTAL
Intervention: Asymptomatic gallstones
Number of subjects: 2034

Group type: COMPARATOR
Intervention: Cholecystectomy (1983)
Number of subjects: 2034

Group type: EXPERIMENTAL
Intervention: Surgically treated SGS (1992-1994)
Number of subjects: 2034

Group type: COMPARATOR
Intervention: AC (surgically treated vs non-surgically treated)
Number of subjects: 2034

Group type: COMPARATOR
Intervention: Mortality in SGS and AC (surgically treated vs non-surgically treated)
Number of subjects: 2034
Study: 22946546

Group type: EXPERIMENTAL
Intervention: Udenafil (50 mg daily) for 8 weeks
Number of subjects: 23
Study: 22947029

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 866
Study: 22948576

Group type: EXPERIMENTAL
Intervention: ECLA
Number of subjects: 37

Group type: COMPARATOR
Intervention: No ECLA
Number of subjects: 37
Study: 22948699

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance (CMR) imaging
Number of subjects: 936

Group type: COMPARATOR
Intervention: Electrocardiography (ECG)
Number of subjects: 936

Group type: COMPARATOR
Intervention: Recognized myocardial infarction (RMI)
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Unrecognized myocardial infarction (UMI) by CMR
Number of subjects: 936

Group type: COMPARATOR
Intervention: No myocardial infarction (MI)
Number of subjects: 936

Group type: COMPARATOR
Intervention: Unrecognized myocardial infarction (UMI) by ECG
Number of subjects: 936
Study: 22951194

Group type: EXPERIMENTAL
Intervention: faecal calprotectin (fCal)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: ileoscopy
Number of subjects: 93

Group type: COMPARATOR
Intervention: small bowel imaging
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: capsule endoscopy
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: MRE and CTE
Number of subjects: 93
Study: 22951377

Group type: COMPARATOR
Intervention: Vastus medialis obliquus (VMO) EMD
Number of subjects: 26

Group type: COMPARATOR
Intervention: Vastus lateralis (VL) EMD
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Comparison of VMO and VL EMD
Number of subjects: 26
Study: 22952183

Group type: EXPERIMENTAL
Intervention: Heme iron intake (≥1.63 mg/d)
Number of subjects: 60895

Group type: EXPERIMENTAL
Intervention: Total iron intake (≥15.09 mg/d)
Number of subjects: 60895

Group type: EXPERIMENTAL
Intervention: Liver intake (≥100 g/wk)
Number of subjects: 60895

Group type: COMPARATOR
Intervention: Red and processed meats intake
Number of subjects: 60895
Study: 22952794

Group type: EXPERIMENTAL
Intervention: Standardized Nursing Care Plans (SNCP)
Number of subjects: 24124

Group type: COMPARATOR
Intervention: Usual Nursing Care (UNC)
Number of subjects: 24124
Study: 22953007

Group type: EXPERIMENTAL
Intervention: Barriers to attendance for surgery
Number of subjects: 2591

Group type: EXPERIMENTAL
Intervention: Fear of surgery
Number of subjects: 2591

Group type: EXPERIMENTAL
Intervention: Awareness of how to access services
Number of subjects: 2591

Group type: EXPERIMENTAL
Intervention: Asymptomatic status
Number of subjects: 2591

Group type: EXPERIMENTAL
Intervention: Offering of TT surgery
Number of subjects: 2591
Study: 22954507

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg orally twice daily in 28-day cycles
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Crizotinib
Number of subjects: 149
Study: 22954655

Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (two doses of a killed whole-cell B-subunit cholera vaccine)
Number of subjects: 48278

Group type: EXPERIMENTAL
Intervention: Indirect (herd) protection from the oral cholera vaccine
Number of subjects: 48278
Study: 22955120

Group type: EXPERIMENTAL
Intervention: Cord blood serum (CBS) eye drops, 0.15 ng per eye per day epithelial growth factor, administered for 1 month.
Number of subjects: 30
Study: 22955296

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 22955317

Group type: EXPERIMENTAL
Intervention: CD11b(+)CD14(+)S100A9(+) cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depletion of CD11b(+)CD14(+) cells in PBMC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isolated CD11b(+)CD14(+) cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inducible nitric oxide synthase (iNOS) inhibitor aminoguanidine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Arginase inhibitor N-hydroxy-nor-l-arginine (nor-NOHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Blocking antibodies for IL-4Rα(+) and IL-10
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ratio of S100A9(+) cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD14(+)S100A9(+) inflammatory monocytes
Number of subjects: 0
Study: 22955319

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: IL-13 stimulation
Number of subjects: 47

Group type: COMPARATOR
Intervention: Steroid-naive asthma
Number of subjects: 47

Group type: COMPARATOR
Intervention: Steroid-using asthma
Number of subjects: 47

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 47
Study: 22955430

Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 200
Study: 22955439

Group type: EXPERIMENTAL
Intervention: Posaconazole
Number of subjects: 515

Group type: COMPARATOR
Intervention: Itraconazole
Number of subjects: 515
Study: 22955514

Group type: EXPERIMENTAL
Intervention: Plasma alkylresorcinols (AR)
Number of subjects: 407
Study: 22956609

Group type: EXPERIMENTAL
Intervention: Subthreshold laser burns with halved energy flux
Number of subjects: 10

Group type: COMPARATOR
Intervention: Threshold power laser burns
Number of subjects: 10
Study: 22956946

Group type: EXPERIMENTAL
Intervention: Guided interaction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Unguided interaction
Number of subjects: 40
Study: 22958032

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mild hypothermia in preterm newborns with necrotizing enterocolitis (NEC) and multiple organ dysfunction syndrome (MODS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 0
Study: 22958075

Group type: EXPERIMENTAL
Intervention: Subarachnoid block
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasonography
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Clinical examination and MRI studies
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CT myelography
Number of subjects: 36
Study: 22958084

Group type: EXPERIMENTAL
Intervention: Agitated saline transcranial Doppler (TCD) monitoring
Number of subjects: 1103

Group type: EXPERIMENTAL
Intervention: Absence of leukoaraiosis (LA)
Number of subjects: 1103
Study: 22959186

Group type: EXPERIMENTAL
Intervention: Regorafenib (160 mg per day)
Number of subjects: 49
Study: 22959621

Group type: EXPERIMENTAL
Intervention: Low glycaemic load breakfast
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High glycaemic load breakfast
Number of subjects: 34

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 34
Study: 22960277

Group type: EXPERIMENTAL
Intervention: Myotonometer measurements of muscle tone, elasticity, and stiffness
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Myotonometer measurements of biceps
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Myotonometer measurements
Number of subjects: 61
Study: 22960352

Group type: EXPERIMENTAL
Intervention: ab-paclitaxel 100mg/m² with bevacizumab 10mg/kg
Number of subjects: 48
Study: 22960783

Group type: EXPERIMENTAL
Intervention: Exercise therapy program
Number of subjects: 20
Study: 22960888

Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cell therapy (mean 80 million cells, CD-34 + mean 0.92 million)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cell therapy
Number of subjects: 11
Study: 22961865

Group type: EXPERIMENTAL
Intervention: Selective V(1a)-agonist Phe(2)-Orn(8)-Vasotocin (POV)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Mixed V(1a)-/V(2)-agonist AVP
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline solution (control)
Number of subjects: 18
Study: 22961962

Group type: EXPERIMENTAL
Intervention: Monitoring of cardiac arrhythmias in acute neurovascular patients during the first 72 hours after admission.
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Monitoring during the first 24 hours after admission.
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Monitoring of serious arrhythmic tachycardia.
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Assessment of arrhythmias in relation to age and neurological deficits.
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Monitoring capabilities based on risk factors.
Number of subjects: 501
Study: 22963265

Group type: EXPERIMENTAL
Intervention: CSF Aβ1-42 ≤ 192 pG/mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: CSF Aβ1-42 > 192 pG/mL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: total-tau/Aβ1-42 > 0.39
Number of subjects: 0

Group type: COMPARATOR
Intervention: total-tau/Aβ1-42 ≤ 0.39
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individuals with lumbar puncture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individuals without lumbar puncture
Number of subjects: 0
Study: 22964015

Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide (ATO) with Ascorbic Acid
Number of subjects: 12
Study: 22964741

Group type: EXPERIMENTAL
Intervention: Expectant observation
Number of subjects: 87

Group type: COMPARATOR
Intervention: Immediate surgical resection
Number of subjects: 87
Study: 22964989

Group type: COMPARATOR
Intervention: High-resolution macular imaging using adaptive optics scanning laser ophthalmoscopy and spectral domain optical coherence tomography.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Best-corrected visual acuity assessment.
Number of subjects: 3

Group type: COMPARATOR
Intervention: Kinetic and static perimetry and full-field electroretinography.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Genetic sequencing of the CLRN1 gene.
Number of subjects: 3
Study: 22965160

Group type: EXPERIMENTAL
Intervention: Leptin treatment
Number of subjects: 1

Group type: COMPARATOR
Intervention: Leptin discontinuation
Number of subjects: 1
Study: 22965568

Group type: EXPERIMENTAL
Intervention: Treatment for clinically localized melanoma
Number of subjects: 100